Company news
Kalvista Pharmaceuticals, Inc. (NASDAQ:KALV) news
Kalvista Pharmaceuticals, Inc. news releases on 6ix. Latest, Jul 24, 2023: KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA…
Press releases — page 3
KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit
July 23, 2023
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit
July 13, 2023
KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology
June 11, 2023
KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
June 1, 2023
KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference
May 30, 2023
KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference
May 22, 2023
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
May 7, 2023
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop
April 26, 2023
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
March 8, 2023
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
February 26, 2023
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
February 15, 2023
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
February 13, 2023
KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
February 9, 2023
KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session
February 6, 2023
KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
February 2, 2023
KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President
January 4, 2023
KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering
December 26, 2022
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
December 7, 2022
KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting
November 13, 2022
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
October 30, 2022
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
October 18, 2022
KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman
October 16, 2022
KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop
October 6, 2022
KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema
October 3, 2022
KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop
September 29, 2022
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
September 7, 2022
KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema
August 22, 2022
KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference
July 18, 2022
KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program
July 4, 2022
KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
June 22, 2022
KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program
June 7, 2022
KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference
May 31, 2022
KalVista Pharmaceuticals Announces Changes to Board of Directors
May 26, 2022
KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900
May 16, 2022
KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference
April 10, 2022
KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy
March 21, 2022
KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial
March 6, 2022
KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients
February 27, 2022
KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
February 2, 2022
KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022
February 1, 2022
KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology
January 23, 2022
KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema
November 9, 2021
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE
November 7, 2021
KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
September 20, 2021
KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824
September 13, 2021
KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema
August 22, 2021
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE
July 11, 2021
KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)
June 27, 2021
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
June 4, 2021